Mansoor Mirza @MirzaCPH X Profile

Mansoor Mirza

@MirzaCPH

Followers

290

Following

12

Media

9

Statuses

34

Joined May 2016

Don't wanna be here? Send us removal request.

Mansoor Mirza

@MirzaCPH

2 years

Exciting data! ENGOT is proud to be enrolling the XPORT-EC-042trial. #esgo2024

MSKCC Team Uterus

@TeamEndo_MSK

2 years

Is selinexor the magic drug in NSMP endometrial cancer ? #esgo2024 An engaging discussion by Dr Sehouli

1

14

Pernille Bjerre Trent

@BjerreTrent

3 years

📢👏🏻🏆Congratulations to @MirzaCPH and the #RUBYtrial team and to patients who hopefully will can benefit from #immuntherapy💉🏥🧪 in advanced #endometrialcarcinoma

Ane Gerda Z Eriksson MD PhD

@agz_eriksson

3 years

@MirzaCPH presenting practice changing Ruby trial results at #SGOmtg ✅Dostarlimab +Carbo/Taxol in advanced&recurrent #EndometrialCancer ✅2yr PFS dMMR 61.4% HR0.28(95%CI 0.16-0.49) ✅2yr OS dMMR 83.3% HR0.30(95%CI 0.13-0.7) ✅dMMR ORR 77.6% w durable response & well-tolerated

0

1

12

NSGO_org

@nsgo_org

3 years

𝐄𝐍𝐆𝐎𝐓, 𝐍𝐒𝐆𝐎-𝐂𝐓𝐔 & 𝐆𝐎𝐆 𝐩𝐫𝐨𝐮𝐝𝐥𝐲 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐠𝐫𝐨𝐮𝐧𝐝-𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐄𝐍𝐆𝐎𝐓-𝐄𝐍6-𝐍𝐒𝐆𝐎/𝐆𝐎𝐆-3031/𝐑𝐔𝐁𝐘 𝐭𝐫𝐢𝐚𝐥. https://t.co/d68OfTbAkx #Endometrial #Cancer #RUBY #NSGO #ENGOT #Dostarlimab #ESMO #SGO

0

3

10

Ane Gerda Z Eriksson MD PhD

@agz_eriksson

3 years

@MirzaCPH presenting practice changing Ruby trial results at #SGOmtg ✅Dostarlimab +Carbo/Taxol in advanced&recurrent #EndometrialCancer ✅2yr PFS dMMR 61.4% HR0.28(95%CI 0.16-0.49) ✅2yr OS dMMR 83.3% HR0.30(95%CI 0.13-0.7) ✅dMMR ORR 77.6% w durable response & well-tolerated

2

17

44

NEJM

@NEJM

3 years

#SGOMtg: A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo. Read full results of RUBY trial: https://t.co/w5JgJbEcoq

1

52

118

Annie Ellis

@Stigetta

3 years

Endometrial cancer patient @researchmatters thanks @SGO_org for all the hard work. Standing ovation!! #SGOmtg #PatientsPurposeProgress #gyncsm

2

9

50

Mansoor Mirza

@MirzaCPH

3 years

Amazing @ESGO_society esgo Council evening

1

3

18

Mansoor Mirza

@MirzaCPH

3 years

The A team

NSGO_org

@nsgo_org

3 years

Happy Holidays from NSGO-CTU 🎄

0

2

NSGO_org

@nsgo_org

3 years

Happy Holidays from NSGO-CTU 🎄

0

1

3

Mansoor Mirza

@MirzaCPH

6 years

@thxtomyfriends

0

1

9

Mansoor Mirza

@MirzaCPH

8 years

EMA London

0

1

Mansoor Mirza

@MirzaCPH

8 years

ESMO 2017 Highlights in Gynaecological Cancers: Hight Quality Data From Randomised Trials - YouTube

0

1

Mansoor Mirza

@MirzaCPH

8 years

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer https://t.co/PCmP5bz4JL via @onclive

0

1

IGCS

@IGCSociety

8 years

Niraparib maintains quality of life in recurrent #ovariancancer https://t.co/M30Zzxhvn3

0

5

7

Morten Hiul Suppli

@MSuppli

8 years

Dr. Mirza @MirzaCPH from @Rigshospitalet on #ovariancancer

The ASCO Post

@ASCOPost

8 years

Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life https://t.co/oXxX75OeAh #gyncsm #ESMO17 #oncology

0

1

Mansoor Mirza

@MirzaCPH

8 years

"Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life" https://t.co/L8cKv0ERfU #oncology via @ascopost

0

Mansoor Mirza

@MirzaCPH

9 years

"Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered" https://t.co/MeGQbo2rAs via @ascopost

0

1

2

Mansoor Mirza

@MirzaCPH

9 years

Niraparib (ZEJULA)

0

3

2

Mansoor Mirza

@MirzaCPH

9 years

#SGOmtg @temkins @bpothuri

0

1

Mansoor Mirza

@MirzaCPH

9 years

#SGOmtg visiting with friends

0

1